Your browser is no longer supported. Please, upgrade your browser.
Settings
NK NantKwest, Inc. daily Stock Chart
NK [NASD]
NantKwest, Inc.
Index- P/E- EPS (ttm)-0.65 Insider Own1.40% Shs Outstand80.26M Perf Week-7.78%
Market Cap123.60M Forward P/E- EPS next Y-1.39 Insider Trans-33.58% Shs Float27.39M Perf Month-41.89%
Income-51.70M PEG- EPS next Q-0.32 Inst Own16.20% Short Float9.77% Perf Quarter-48.32%
Sales0.05M P/S2376.93 EPS this Y62.30% Inst Trans-0.71% Short Ratio4.97 Perf Half Y-57.92%
Book/sh2.05 P/B0.75 EPS next Y5.10% ROA-46.30% Target Price3.25 Perf Year-69.20%
Cash/sh1.05 P/C1.47 EPS next 5Y-1.70% ROE-54.20% 52W Range1.52 - 5.47 Perf YTD-65.70%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-71.85% Beta3.05
Dividend %- Quick Ratio3.30 Sales past 5Y- Gross Margin- 52W Low1.32% ATR0.27
Employees169 Current Ratio3.30 Sales Q/Q287.50% Oper. Margin- RSI (14)28.97 Volatility11.81% 13.67%
OptionableYes Debt/Eq0.05 EPS Q/Q1.10% Profit Margin- Rel Volume0.30 Prev Close1.56
ShortableYes LT Debt/Eq0.04 EarningsNov 13 Payout- Avg Volume537.93K Price1.54
Recom3.70 SMA20-27.68% SMA50-43.03% SMA200-54.20% Volume160,154 Change-1.28%
Nov-30-18Upgrade Citigroup Sell → Neutral
Oct-17-18Downgrade Citigroup Neutral → Sell
Aug-09-18Upgrade Citigroup Sell → Neutral
May-16-17Downgrade Citigroup Neutral → Sell
Mar-17-17Reiterated FBR & Co. Outperform $22 → $9
Jan-24-17Downgrade Jefferies Buy → Hold
Jun-02-16Initiated Raymond James Mkt Perform
Apr-04-16Reiterated Canaccord Genuity Buy $20 → $18
Mar-31-16Reiterated FBR Capital Outperform $30 → $29
Dec-22-15Initiated Canaccord Genuity Buy $20
Oct-28-15Initiated FBR Capital Outperform $30
Aug-24-15Initiated Piper Jaffray Overweight $38
Aug-24-15Initiated MLV & Co Buy $35
Aug-24-15Initiated Jefferies Buy $33
Aug-24-15Initiated Citigroup Buy $45
Dec-03-18 11:00AM  NantKwest to Present Updated Preclinical Data at the 60th Annual Meeting of the American Society of Hematology Business Wire
Nov-08-18 12:56PM  Here's Why NantKwest Skyrocketed 26.4% Today Motley Fool +37.27%
10:20AM  Healthcare Stocks are Gaining Ground in Technology Niche: Premier Health Group, Inc. (OTC: PHGRF) (CSE: PHGI), Inovalon Holdings, NantKwest Inc. ACCESSWIRE
Nov-07-18 05:28PM  NantKwest Announces Promising First in Human Clinical Results of 300 Doses Of CD16 Targeted, Off-The-Shelf Cryopreserved Natural Killer Cells (haNK) in a Novel Cancer Memory Vaccine Immunotherapy Business Wire
Nov-05-18 11:23PM  NantKwest Announces Multiple Presentations at the 2018 Society for Immunotherapy of Cancer Conference Business Wire
Oct-23-18 08:00AM  Investor Expectations to Drive Momentum within Navios Maritime Partners LP, Alliance Data, Eli Lilly, CONVERGEONE HLD, Atkore International Group, and NantKwest Discovering Underlying Factors of Influence GlobeNewswire
06:05AM  NantKwest Sees Hammer Chart Pattern: Time to Buy? Zacks
Oct-02-18 12:02PM  NantKwest to Present at 2018 Cantor Global Healthcare Conference Business Wire +10.11%
Sep-18-18 01:52PM  Who Are The Top Investors In NantKwest Inc (NASDAQ:NK)? Simply Wall St.
Aug-29-18 08:30AM  Report: Exploring Fundamental Drivers Behind Navios Maritime Partners LP, CONVERGEONE HLD, Greenbrier Companies, NantKwest, Genpact, and Textainer Group New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Aug-10-18 03:08PM  Citigroup Upgrades NantKwest, But Finds Six Reasons To Stay On Sidelines Benzinga
Jul-02-18 08:10AM  Report: Exploring Fundamental Drivers Behind Telecom Argentina, GasLog, National Retail Properties, Appian, Zscaler, and NantKwest New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire -6.21%
Jun-19-18 05:00AM  NantKwest Names Sonja Nelson Chief Financial Officer Business Wire -8.20%
Jun-11-18 07:08AM  Biotech's Soon-Shiong hiring bankers for Nant cancer drug IPO Reuters
07:00AM  Biotech's Soon-Shiong hiring bankers for Nant cancer drug IPO Reuters
Jun-05-18 01:29PM  NantKwest to Present at Jefferies 2018 Global Healthcare Conference Business Wire
Apr-23-18 03:18PM  NantKwest to Present at Upcoming Science & Medicine Conferences Business Wire
Mar-13-18 07:29PM  NantKwest to Present at Upcoming Investment and Healthcare Conferences Business Wire -6.72%
02:49PM  Rockville biotech founded by L.A. billionaire to lay off 52 American City Business Journals
Feb-13-18 08:00AM  Nantkwest and Frankfurt University Hospital Announce First in Human Dosing of off-the-Shelf HER2.taNK (Carnatural Killer) Cell Therapy in Glioblastoma Business Wire +12.41%
Feb-06-18 08:25AM  New Research Coverage Highlights Atara Biotherapeutics, SPX, Entellus Medical, Columbus McKinnon, NantKwest, and Merrimack Pharmaceuticals Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire +9.19%
Jan-30-18 09:06AM  Putin says U.S. is taking 'hostile step' Yahoo Finance
07:20AM  Yahoo Finance Live: Market Movers - Jan 30th, 2018 Yahoo Finance Video
Jan-24-18 02:05PM  3 Stocks Under $10 That Surged Yesterday InvestorPlace -6.40%
Jan-23-18 06:44PM  3 Stocks Under $10 That Surged Today Zacks +12.74%
Jan-05-18 06:03PM  NantWorks to Present Healthcare and Biotechnology Platforms at 36th Annual J.P. Morgan Healthcare Conference on January 9, 2018 in San Francisco, CA Business Wire
03:44AM  NantKwest to Host 3rd Annual Investor/Analyst Day Highlighting a Record Number of 15 INDs Authorized in 2017 Covering 12 Tumor Types with First In-Human Clinical Data of Safety and Early Signs of Clinical Activity of the NANT Cancer Vaccine Business Wire
Dec-28-17 12:30PM  ETFs with exposure to NantKwest, Inc. : December 28, 2017 Capital Cube
Dec-27-17 08:35AM  NantKwest, Inc. :NK-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 Capital Cube
Dec-12-17 09:45AM  Update in Lawsuit for Investors in Nantkwest Inc. (NASDAQ: NK) Shares Announced by Shareholders Foundation ACCESSWIRE
Dec-04-17 08:00AM  NantKwest to Present Data at the 59th Annual Meeting of the American Society of Hematology Business Wire
Nov-21-17 07:59AM  NantKwest, Inc. breached its 50 day moving average in a Bearish Manner : NK-US : November 21, 2017 Capital Cube
Oct-24-17 04:51PM  Lifshitz & Miller LLP Announces Investigation of AmTrust Financial Services Inc., Axon Enterprise, Inc., Diana Containerships Inc., Kobe Steel, Ltd., NantKwest, Inc., Skechers U.S.A., Inc. and Tesla, Inc. PR Newswire
Oct-11-17 11:52AM  ETFs with exposure to NantKwest, Inc. : October 11, 2017 Capital Cube
Oct-04-17 09:30AM  Johnson Fistel, Announces Investigations of NantKwest, Inc., K12 Inc., and CytRx Corporation; Long-Term Investors Encouraged to Contact Firm PR Newswire
Sep-26-17 10:59AM  ETFs with exposure to NantKwest, Inc. : September 26, 2017 Capital Cube
Sep-22-17 04:39PM  NantKwest Builds Financial and Commercial Expertise with the Appointment of Fred Driscoll to Its Board of Directors Business Wire
Sep-21-17 08:01AM  NANTKWEST (NK) SHAREHOLDER ALERT Andrews & Springer LLC is Investigating NantKwest, Inc. for Potential Breaches of Fiduciary Duty Business Wire
Aug-31-17 07:38PM  ETFs with exposure to NantKwest, Inc. : August 31, 2017 Capital Cube +9.88%
Aug-24-17 10:11AM  NantKwest, Inc. :NK-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube +6.14%
Aug-15-17 06:18PM  NantKwest, Inc. Value Analysis (NASDAQ:NK) : August 15, 2017 Capital Cube
Aug-09-17 11:50AM  Here's Why NantKwest Inc. Tumbled 21.1% in July Motley Fool
Aug-07-17 12:59PM  NantKwest to Present at the 37th Annual Canaccord Genuity Growth Conference Business Wire
Aug-02-17 09:12AM  NantKwest, Inc. breached its 50 day moving average in a Bearish Manner : NK-US : August 2, 2017 Capital Cube
Jul-31-17 11:00AM  NantKwest Announces Durable Complete Responses in Phase I Trial of aNK Cell Therapy in Patients with Relapsed Hematological Malignancies Business Wire
Jul-27-17 09:00AM  Haeggquist & Eck Investigates NantKwest for Misrepresenting Compensation to CEO by $49 Million and Breach of Fiduciary Duty Business Wire -7.83%
Jul-25-17 08:00AM  NantKwest Announces Publication of Preclinical Data of haNK Cell Therapy in Combination with Checkpoint Inhibitor Avelumab Providing Strong Rationale for Advancement to Human Clinical Trials Business Wire
Jul-18-17 08:10AM  5 CAR-T Stocks in Focus as NVS Drug Wins FDA Advisory Panel Vote Zacks
Jul-14-17 09:00AM  Haeggquist & Eck, LLP Investigates NantKwest Inc. for Potential Breaches of Fiduciary Duty by Its Board of Directors Business Wire
Jun-21-17 09:30AM  Zacks.com featured highlights: Johnson & Johnson, NantKwest, Delek US Holdings, Abbot Labs and Winnebago Zacks -5.79%
Jun-20-17 05:37PM  How to Uncover Institutional Buying Zacks
Jun-19-17 03:48PM  ETFs with exposure to NantKwest, Inc. : June 19, 2017 Capital Cube +9.26%
Jun-16-17 08:15AM  NantKwest (NK) Looks Good: Stock Moves Up 8.5% in Session Zacks +5.37%
Jun-14-17 02:09PM  2 Longs And 2 Shorts To Watch Benzinga
Jun-06-17 08:00AM  NantKwest Expands NANT Cancer Vaccine Program With Additional Clinical Trials Announced Addressing Multiple Cancer Types Across All Stages of Disease Business Wire +6.27%
Jun-02-17 06:55AM  NantKwest to Present at the Jefferies Healthcare Conference on June 7, 2017 Business Wire +6.48%
May-23-17 09:29AM  Biotech Movers: Cerus, Alexion, NantKwest TheStreet.com +6.46%
May-18-17 08:00AM  NantKwest Appoints Dr. John Lee as Senior Vice President of Adult Medical Affairs Business Wire
May-16-17 05:02PM  Why Rite Aid, H&R Block, and NantKwest Slumped Today Motley Fool -17.17%
08:00AM  NantKwest Appoints Dr. Leonard Sender as Senior Vice President of Medical Affairs for Pediatric, Adolescent and Young Adult Oncology Business Wire
May-15-17 06:24PM  NantKwest to Present at 2017 Bank of America Merrill Lynch Healthcare Conference Business Wire +15.58%
04:15PM  ETFs with exposure to NantKwest, Inc. : May 15, 2017 Capital Cube
02:34PM  Why NantKwest Stock Is Spiking Today Motley Fool
08:17AM  NantKwest, Inc. breached its 50 day moving average in a Bullish Manner : NK-US : May 15, 2017 Capital Cube
May-10-17 10:52AM  NantKwest, Inc. :NK-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017 Capital Cube
May-09-17 07:00AM  NantKwest and NantCell Announce FDA Authorization for the NANT Cancer Vaccine Clinical Trials, the First Novel Combination of Innate and Adaptive Immunotherapy in Patients with Pancreatic Cancer Business Wire +9.19%
06:00AM  NantKwest reports 1Q loss Associated Press
May-04-17 04:11PM  ETFs with exposure to NantKwest, Inc. : May 4, 2017 Capital Cube
Apr-24-17 02:37PM  ETFs with exposure to NantKwest, Inc. : April 24, 2017 Capital Cube
Apr-07-17 05:08PM  ETFs with exposure to NantKwest, Inc. : April 7, 2017 Capital Cube
Apr-04-17 03:03PM  [$$] Funding Snapshot: Viracta Gets $18.4 Million from NantKwest for Cancer Drugs The Wall Street Journal
03:03PM  [$$] Funding Snapshot: Viracta Gets $18.4 Million from NantKwest for Cancer Drugs
08:00AM  NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership GlobeNewswire
08:00AM  NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership
Mar-27-17 04:01PM  ETFs with exposure to NantKwest, Inc. : March 27, 2017 Capital Cube +6.19%
04:01PM  ETFs with exposure to NantKwest, Inc. : March 27, 2017
Mar-21-17 01:04PM  NANTKWEST, INC. Financials -6.76%
11:38AM  NantKwest, Inc. :NK-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Capital Cube
11:38AM  NantKwest, Inc. :NK-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
09:59AM  NantKwest, Inc. :NK-US: Earnings Analysis: 2016 By the Numbers : March 21, 2017
Mar-20-17 07:00AM  NantKwest Announces FDA Grant of Orphan Drug Designation for the Companys aNK Natural Killer Cell Therapy in Merkel Cell Carcinoma Business Wire
Mar-15-17 04:22PM  NANTKWEST, INC. Files SEC form 10-K, Annual Report +7.02%
Mar-06-17 05:00AM  NantKwest to Present at Upcoming Investor Conferences Business Wire -5.15%
Jan-24-17 09:26AM  Biotech Premarket Movers: Amicus Therapeutics, Nantkwest and Organovo -11.44%
06:44AM  NantKwest downgraded by Jefferies
Jan-23-17 12:47PM  Landmark First-In-Human Clinical Study Launch Using a Genetically Engineered Natural Killer Cell for the Treatment of Cancer Business Wire
Jan-11-17 11:18AM  NantKwest, Inc. Value Analysis (NASDAQ:NK) : January 11, 2017 Capital Cube
11:18AM  NantKwest, Inc. Value Analysis (NASDAQ:NK) : January 11, 2017
Jan-10-17 07:19AM  NantKwest, Inc. breached its 50 day moving average in a Bullish Manner : NK-US : January 10, 2017 Capital Cube
07:19AM  NantKwest, Inc. breached its 50 day moving average in a Bullish Manner : NK-US : January 10, 2017
Dec-19-16 05:00AM  NantKwest to Host 2nd Annual Investor/Analyst Day Highlighting Industry Leading R&D and Clinical Programs Business Wire
Dec-16-16 02:05PM  ETFs with exposure to NantKwest, Inc. : December 16, 2016
12:13AM  How Nantkwest Inc (NK) Stacks Up Versus Peers at Insider Monkey
Dec-12-16 11:44AM  NantKwest Announces Enhanced High-Affinity Activated Natural Killer (haNK) Cell Therapy in Preclinical Studies of HER2 Positive Breast Cancer at Presentation at the San Antonio Breast Cancer Symposium Business Wire
Dec-08-16 08:43AM  Why NantKwest (NK) Stock Might be a Great Pick
Nov-29-16 07:27AM  NantKwest, Inc. breached its 50 day moving average in a Bearish Manner : NK-US : November 29, 2016
Nov-28-16 01:13PM  NantKwest to Present at the Piper Jaffray 28th Annual Health Care Conference Business Wire
Nov-23-16 01:17PM  ETFs with exposure to NantKwest, Inc. : November 23, 2016
Nov-22-16 08:17PM  Direct Injection of CAR-Engineered CD19.taNK Cells Demonstrating Potential Vaccine Protective Effect to be Highlighted in Oral Presentation at the 58th Annual Meeting of the American Society of Hematology Business Wire
11:43AM  NantKwest Announces Landmark Study Published on high affinity haNK Cell Therapy in the Journal Oncotarget Business Wire
NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer product candidates primarily for the treatment of various cancers; and target activated natural killer product candidates to treat hematological malignancies and solid tumors. NantKwest, Inc. has a co-development agreement with Altor Bio Science Corporation to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GORLIN STEVEDirectorNov 29Sale1.65138,349228,2760Dec 03 05:44 PM
GORLIN STEVEDirectorNov 29Sale1.7034,01957,785138,349Nov 29 07:36 PM
GORLIN STEVEDirectorNov 28Sale1.7617,14030,125172,368Nov 29 07:36 PM
GORLIN STEVEDirectorNov 27Sale1.75100,000175,200189,508Nov 29 07:36 PM
GORLIN STEVEDirectorNov 23Sale2.019,31218,717289,508Nov 26 07:21 PM
GORLIN STEVEDirectorNov 21Sale2.0222,90046,217298,820Nov 26 07:21 PM
GORLIN STEVEDirectorNov 14Sale2.21115,930255,7180Nov 14 08:07 PM
GORLIN STEVEDirectorNov 13Sale2.4033,30079,887115,930Nov 14 08:07 PM
GORLIN STEVEDirectorNov 12Sale2.4347,050114,463149,230Nov 14 08:07 PM
GORLIN STEVEDirectorAug 27Sale3.0918,30056,463196,280Aug 27 07:47 PM
GORLIN STEVEDirectorAug 24Sale3.0710,22531,341214,580Aug 27 07:47 PM
GORLIN STEVEDirectorAug 23Sale3.0621,47565,709224,805Aug 27 07:47 PM
SOON-SHIONG PATRICKChairman and CEOJul 11Option Exercise1.629,25715,00040,565,814Jul 13 07:26 PM
GORLIN STEVEDirectorJun 07Sale3.6626,95798,614321,720Jun 07 08:21 PM
GORLIN STEVEDirectorJun 06Sale3.7923,57489,272348,677Jun 07 08:21 PM
GORLIN STEVEDirectorJun 05Sale3.7528,925108,339372,251Jun 07 08:21 PM
GORLIN STEVEDirectorMay 30Sale3.882,72410,564401,176Jun 01 04:23 PM
GORLIN STEVEDirectorMay 29Sale3.892,1008,175403,900May 29 07:53 PM
GORLIN STEVEDirectorMay 25Sale3.973,60014,294406,000May 29 07:53 PM
GORLIN STEVEDirectorMay 24Sale3.963031,200409,600May 29 07:53 PM
GORLIN STEVEDirectorMay 22Sale3.818,54632,560409,903May 23 09:38 PM
GORLIN STEVEDirectorMay 21Sale3.905,55721,672418,449May 23 09:38 PM
GORLIN STEVEDirectorMay 18Sale3.9715,97163,413424,006May 22 08:41 PM
GORLIN STEVEDirectorMay 17Sale4.0038,708154,929439,977May 17 06:53 PM
GORLIN STEVEDirectorMay 16Sale4.0516,20065,634478,685May 17 06:53 PM
GORLIN STEVEDirectorMay 15Sale4.1326,835110,890494,885May 17 06:53 PM
Nelson SonjaChief Accounting OfficerMar 23Option Exercise0.0015,000015,000Mar 26 06:55 PM